{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:11:04Z","timestamp":1791522664302,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["16\/136\/46"],"award-info":[{"award-number":["16\/136\/46"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["208812\/Z\/17\/Z"],"award-info":[{"award-number":["208812\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the population size benefiting from pneumococcal vaccines and robustness of immunogenic response to vaccination decline. We estimate how demographics, vaccine efficacy\/effectiveness (VE), and waning VE impact on optimal age for a single-dose pneumococcal vaccination. Age- and vaccine-serotype-specific IPD cases from routine surveillance of adults \u2265\u200955 years old (y), \u2265\u20094-years after infant-pneumococcal vaccine introduction and before 2020, and VE data from prior studies were used to estimate IPD incidence and waning VE which were then combined in a cohort model of vaccine impact. In Brazil, Malawi, South Africa and England 51, 51, 54 and 39% of adults older than 55\u2009y were younger than 65\u2009years old, with a smaller share of annual IPD cases reported among &lt;\u200965\u2009years old in England (4,657; 20%) than Brazil (186; 45%), Malawi (4; 63%), or South Africa (134, 48%). Vaccination at 55\u2009years in Brazil, Malawi, and South Africa, and at 70\u2009years in England had the greatest potential for IPD prevention. Here, we show that in low\/middle-income countries, pneumococcal vaccines may prevent a substantial proportion of residual IPD burden if administered earlier in adulthood than is typical in high-income countries.<\/jats:p>","DOI":"10.1038\/s41467-023-36624-8","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:02:57Z","timestamp":1676541777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Optimal age targeting for pneumococcal vaccination in older adults; a modelling study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-7862","authenticated-orcid":false,"given":"Deus","family":"Thindwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-6273","authenticated-orcid":false,"given":"Jackie","family":"Kleynhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-7455","authenticated-orcid":false,"given":"Anne","family":"von Gottberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibongile","family":"Walaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4508-5469","authenticated-orcid":false,"given":"Susan","family":"Meiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-7039","authenticated-orcid":false,"given":"Todd D.","family":"Swarthout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahin","family":"Amin-Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-6507","authenticated-orcid":false,"given":"Norman","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-2210","authenticated-orcid":false,"given":"Kondwani C.","family":"Jambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta Cristine Grassi","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-449X","authenticated-orcid":false,"given":"Robert S.","family":"Heyderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-2302","authenticated-orcid":false,"given":"Cheryl","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"de Cunto Brandileone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-2606","authenticated-orcid":false,"given":"Stefan","family":"Flasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"36624_CR1","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl, B. et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315. Lancet Glob. Health 6, e744\u2013e757 (2018).","journal-title":"Lancet Glob. Health"},{"key":"36624_CR2","unstructured":"Department of Immunization, Vaccines and Biologicals. WHO | SAGE Yellow Book for October 2020. 20 http:\/\/www.who.int\/immunization\/sage\/meetings\/2020\/october\/presentations_background_docs\/en\/ (2020)."},{"key":"36624_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/microorganisms9040742","volume":"9","author":"M Deloria Knoll","year":"2021","unstructured":"Deloria Knoll, M. et al. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10\/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms 9, 742 (2021).","journal-title":"Microorganisms"},{"key":"36624_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10096-019-03485-3","volume":"38","author":"C Bonnave","year":"2019","unstructured":"Bonnave, C. et al. Adult vaccination for pneumococcal disease: A comparison of the national guidelines in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 38, 785\u2013791 (2019).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"36624_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1045","author":"D Hurley","year":"2021","unstructured":"Hurley, D. et al. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1045 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"36624_CR6","unstructured":"CDC Advisory Committee on Immunization Practices (ACIP). EtR for PCV15 use among adults \u226565 years old | CDC. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/pneumo-PCV15-PPSV23-age-based-etr.html (2022)."},{"key":"36624_CR7","doi-asserted-by":"publisher","first-page":"e1001839","DOI":"10.1371\/journal.pmed.1001839","volume":"12","author":"S Flasche","year":"2015","unstructured":"Flasche, S. et al. The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. PLOS Med 12, e1001839 (2015).","journal-title":"PLOS Med"},{"key":"36624_CR8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","volume":"371","author":"A von Gottberg","year":"2014","unstructured":"von Gottberg, A. et al. Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. N. Engl. J. Med. 371, 1889\u20131899 (2014).","journal-title":"N. Engl. J. Med."},{"key":"36624_CR9","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1016\/S2214-109X(21)00165-0","volume":"9","author":"N Bar-Zeev","year":"2021","unstructured":"Bar-Zeev, N. et al. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006\u201318: prospective observational time-series and case-control studies. Lancet Glob. Health 9, e989\u2013e998 (2021).","journal-title":"Lancet Glob. Health"},{"key":"36624_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/microorganisms9040738","volume":"9","author":"M Garcia Quesada","year":"2021","unstructured":"Garcia Quesada, M. et al. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10\/13 Period: Findings from the PSERENADE Project. Microorganisms 9, 738 (2021).","journal-title":"Microorganisms"},{"key":"36624_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15786-9","volume":"11","author":"TD Swarthout","year":"2020","unstructured":"Swarthout, T. D. et al. High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nat. Commun. 11, 2222 (2020).","journal-title":"Nat. Commun."},{"key":"36624_CR12","first-page":"1","volume":"0","author":"D Thindwa","year":"2020","unstructured":"Thindwa, D. et al. Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa. Expert Rev. Vaccines 0, 1\u20138 (2020).","journal-title":"Vaccines"},{"key":"36624_CR13","unstructured":"VACFA. Immunization Schedules\u2014Africa | Vaccines for Africa. http:\/\/www.vacfa.uct.ac.za\/immunization-schedules-africa (2018)."},{"key":"36624_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","volume":"68","author":"A Matanock","year":"2019","unstructured":"Matanock, A. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u226565 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly. Rep. 68, 1069\u20131075 (2019).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"36624_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.vaccine.2018.01.052","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen, C. et al. The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. Vaccine 36, 1265\u20131271 (2018).","journal-title":"Vaccine"},{"key":"36624_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/INF.0000000000003277","volume":"40","author":"S Senders","year":"2021","unstructured":"Senders, S. et al. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr. Infect. Dis. J. 40, 944\u2013951 (2021).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"36624_CR17","unstructured":"Merck. Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults. Merck.com https:\/\/www.merck.com\/news\/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ\/."},{"key":"36624_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/jamainternmed.2016.8289","volume":"177","author":"DM Weinberger","year":"2017","unstructured":"Weinberger, D. M., Harboe, Z. B. & Shapiro, E. D. Developing Better Pneumococcal Vaccines for Adults. JAMA Intern. Med. 177, 303\u2013304 (2017).","journal-title":"JAMA Intern. Med."},{"key":"36624_CR19","unstructured":"Johnson, L. & Dorrington, R. Thembisa Project\u2014A Mathematical Model of South African HIV epidemic. https:\/\/www.thembisa.org\/ (2022)."},{"key":"36624_CR20","doi-asserted-by":"publisher","first-page":"e1001873","DOI":"10.1371\/journal.pmed.1001873","volume":"12","author":"AT Choko","year":"2015","unstructured":"Choko, A. T. et al. Uptake, accuracy, safety, and linkage into care over two years of promoting annual self-testing for HIV in Blantyre, Malawi: A community-based prospective study. PLOS Med 12, e1001873 (2015).","journal-title":"PLOS Med"},{"key":"36624_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01601-1","volume":"18","author":"S Flasche","year":"2020","unstructured":"Flasche, S., Lipsitch, M., Ojal, J. & Pinsent, A. Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: A modelling study. BMC Med 18, 129 (2020).","journal-title":"BMC Med"},{"key":"36624_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","volume":"71","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi, M. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the advisory committee on immunization practices\u2014United States, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 109\u2013117 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"36624_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/vaccines7010004","volume":"7","author":"E Linley","year":"2019","unstructured":"Linley, E., Bell, A., Gritzfeld, J. F. & Borrow, R. Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays? Vaccines 7, 4 (2019).","journal-title":"Vaccines"},{"key":"36624_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","volume":"6","author":"A Djennad","year":"2019","unstructured":"Djennad, A. et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine 6, 42\u201350 (2019).","journal-title":"EClinicalMedicine"},{"key":"36624_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/21645515.2015.1117713","volume":"12","author":"AL Andrade","year":"2016","unstructured":"Andrade, A. L. et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Hum. Vaccines Immunother. 12, 285\u2013292 (2016).","journal-title":"Hum. Vaccines Immunother."},{"key":"36624_CR26","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2214-109X(17)30043-8","volume":"5","author":"C Cohen","year":"2017","unstructured":"Cohen, C. et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: A case-control study. Lancet Glob. Health 5, e359\u2013e369 (2017).","journal-title":"Lancet Glob. Health"},{"key":"36624_CR27","doi-asserted-by":"publisher","first-page":"e1002845","DOI":"10.1371\/journal.pmed.1002845","volume":"16","author":"YH Choi","year":"2019","unstructured":"Choi, Y. H., Andrews, N. & Miller, E. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study. PLOS Med. 16, e1002845 (2019).","journal-title":"PLOS Med."},{"key":"36624_CR28","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.vaccine.2018.04.010","volume":"36","author":"M-CC Brandileone","year":"2018","unstructured":"Brandileone, M.-C. C., Almeida, S. C. G., Minamisava, R. & Andrade, A.-L. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine 36, 2559\u20132566 (2018).","journal-title":"Vaccine"},{"key":"36624_CR29","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","volume":"30","author":"NJ Andrews","year":"2012","unstructured":"Andrews, N. J., Waight, P. A., George, R. C., Slack, M. P. E. & Miller, E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 30, 6802\u20136808 (2012).","journal-title":"Vaccine"},{"key":"36624_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4161\/hv.7.10.15987","volume":"7","author":"JT Neto","year":"2011","unstructured":"Neto, J. T. et al. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in S\u00e3o Paulo State, Brazil. Hum. Vaccin. 7, 1037\u20131047 (2011).","journal-title":"Hum. Vaccin."},{"key":"36624_CR31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.21037\/jtd.2017.05.31","volume":"9","author":"TH Boyles","year":"2017","unstructured":"Boyles, T. H. et al. South African guideline for the management of community-acquired pneumonia in adults. J. Thorac. Dis. 9, 1469\u20131502 (2017).","journal-title":"J. Thorac. Dis."},{"key":"36624_CR32","unstructured":"Wasm\u00c6lia, B. et al. Censo Demografico 2010 Brazil. Caracter\u00edsticas da popula\u00e7\u00e3o e dos domic\u00edlios Resultados do universo. 1\u2013270 https:\/\/biblioteca.ibge.gov.br\/visualizacao\/periodicos\/93\/cd_2010_caracteristicas_populacao_domicilios.pdf (2011)."},{"key":"36624_CR33","unstructured":"Office for National Statistics UK. Estimates of the Population for the UK, England and Wales, Scotland and Northen Ireland 2017. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates (2017)."},{"key":"36624_CR34","unstructured":"National Statistical Office Malawi. Malawi Population and Housing Census 2018. 1\u2013311 http:\/\/www.nsomalawi.mw\/index.php%3Foption%3Dcom_content%26view%3Darticle%26id%3D226:2018-malawi-population-and-housing-census%26catid%E2%80%89%3D%E2%80%898:reports%26Itemid%E2%80%89%3D%E2%80%896 (2019)."},{"key":"36624_CR35","unstructured":"Statistics South Africa. South Africa Population Census 2011. http:\/\/www.statssa.gov.za\/?page_id=3992 (2011)."},{"key":"36624_CR36","unstructured":"World Bank Group. World Population Annual Growth. https:\/\/data.worldbank.org\/indicator\/SP.POP.GROW? (2021)."},{"key":"36624_CR37","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1890\/0012-9658(2002)083[1928:DSATVR]2.0.CO;2","volume":"83","author":"GA Fox","year":"2002","unstructured":"Fox, G. A. & Kendall, B. E. Demographic Stochasticity and the variance reduction effect. Ecology 83, 1928\u20131934 (2002).","journal-title":"Ecology"},{"key":"36624_CR38","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/cid\/ciz404","volume":"70","author":"C Chaguza","year":"2020","unstructured":"Chaguza, C. et al. Early signals of vaccine-driven perturbation seen in pneumococcal carriage population genomic data. Clin. Infect. Dis. 70, 1294\u20131303 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"36624_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-019-1200-9","volume":"570","author":"L Dwyer-Lindgren","year":"2019","unstructured":"Dwyer-Lindgren, L. et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature 570, 189 (2019).","journal-title":"Nature"},{"key":"36624_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.trivac.2013.09.004","volume":"2","author":"LB Wright","year":"2013","unstructured":"Wright, L. B., Hughes, G. J., Chapman, K. E., Gorton, R. & Wilson, D. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006\u2013July 2012. Trials Vaccinol. 2, 45\u201348 (2013).","journal-title":"Trials Vaccinol."},{"key":"36624_CR41","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1016\/j.vaccine.2013.09.049","volume":"31","author":"W Rudnick","year":"2013","unstructured":"Rudnick, W. et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995\u20132011. Vaccine 31, 5863\u20135871 (2013).","journal-title":"Vaccine"},{"key":"36624_CR42","first-page":"20922","volume":"19","author":"MAG Rodr\u00edguez","year":"2014","unstructured":"Rodr\u00edguez, M. A. G. et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008\u20132011. Eurosurveillance 19, 20922 (2014).","journal-title":"Eurosurveillance"},{"key":"36624_CR43","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJM Bonten","year":"2015","unstructured":"Bonten, M. J. M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372, 1114\u20131125 (2015).","journal-title":"N. Engl. J. Med."},{"key":"36624_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trivac.2016.04.004","volume":"5","author":"S Patterson","year":"2016","unstructured":"Patterson, S. et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 5, 92\u201396 (2016).","journal-title":"Trials Vaccinol."},{"key":"36624_CR45","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/cid\/civ686","volume":"61","author":"CH van Werkhoven","year":"2015","unstructured":"van Werkhoven, C. H., Huijts, S. M., Bolkenbaas, M., Grobbee, D. E. & Bonten, M. J. M. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin. Infect. Dis. 61, 1835\u20131838 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"36624_CR46","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.7592905","author":"D Thindwa","year":"2022","unstructured":"Thindwa, D. & Clifford, S. Optimal age targeting for pneumococcal vaccination in older adults; A modelling study. Zenodo https:\/\/doi.org\/10.5281\/zenodo.7592905 (2022).","journal-title":"Zenodo"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36624-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36624-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36624-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:07:14Z","timestamp":1676542034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36624-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36624"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36624-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.07.22282045","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"888"}}